Brought to you by 
Angiogene licenses restenosis therapy from U. of Montreal
18 Sep 2013
Executive Summary
Angiogene Inc. licensed its molecular radiotherapy technology, OliGlow from the Unversity of Montreal's Centre Hospitalier. OliGlow uses short DNA sequences to target beta-emitting radiation to the nucleus of cells.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Angiogene licenses restenosis therapy from U. of Montreal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice